The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
Category: Novo Nordisk A/S
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.
-
Costco to Sell Ozempic and Wegovy, Weight-Loss Wonder Drugs
Costco members will pay $499 a month out of pocket, the same price offered at CVS and Walmart, and on the manufacturer’s direct-to-consumer website.
-
How Private Equity Oversees the Ethics of Drug Research
Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety.
-
Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growth
Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too.
-
Ozempic Maker Novo Nordisk to Cut 9,000 Jobs
The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and consumer-focused market.
-
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them
President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.
-
Ozempic Maker’s Stock Plunges 20% After Profit Warning
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
-
Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.